Zogenix (ZGNX) Zohydro ER Fails to Win FDA Panel Backing
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/26/2024
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Union Pacific beats profit estimates on stronger pricing, resumes share buyback
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hertz Global (HTZ) misses earnings expectations as fleet costs weigh
- Teladoc (TDOC) Misses Q1 EPS by 3c, offers outlook
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Oppenheimer Downgrades Zogenix, Inc. (ZGNX) to Perform
December 10, 2012 8:12 AM ESTOppenheimer downgraded Zogenix, Inc. (NASDAQ: ZGNX) from Outperform to Perform after the company fails to win FDA panel backing for Zohydro.
The firm comments, "On 12/7, ZGNX's Zohydro did not receive a positive recommendation from an FDA Advisory Committee, which cited safety concerns,... More
Zogenix's (ZGNX) Zohydro Unsafe to Treat Intended Patients, FDA Panel Says
December 7, 2012 3:29 PM ESTThe FDA panel now says that Zogenix's (NASDAQ: ZGNX) Zohydro is unsafe for intended patients. The panel voted 9 - 5 that the painkiller is unsafe.... More
FDA Panel Says Zogenix (ZGNX) Zohydro ER Effective to Treat Pain
December 7, 2012 2:54 PM ESTZogenix (NASDAQ: ZGNX) Zohydro ER effective to treat pain, FDA says. The vote was tight at 7 - 6.... More
Zogenix (ZGNX) Halted Ahead of FDA Committee Meeting for Zohydro ER NDA
December 7, 2012 7:02 AM ESTZogenix, Inc. (Nasdaq: ZGNX) announced that NASDAQ halted trading of the company's common stock on December 7, 2012. The U.S. Food and Drug Administration's (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) is meeting today to review the Company's New Drug Application (NDA) for Zohydro ER (hydrocodone bitartrate extended-release capsules).... More
Zogenix (ZGNX) On Watch After FDA Briefing Docs Posted
December 5, 2012 8:06 AM ESTZogenix, Inc. (NASDAQ: ZGNX) is on watch as FDA briefing documents are posted.
Link... More
